Trial Profile
A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2024
Price :
$35
*
At a glance
- Drugs BP 1002 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bio-Path Holdings
- 02 Apr 2024 Results presented at a Bio-Path Holdings Media Release
- 02 Apr 2024 According to a Bio-Path Holdings media release,Enrollment is now open for patients for the second BP1002 dose cohort of 40 mg/m2.
- 02 Apr 2024 According to a Bio-Path Holdings media release, trial is being conducted at the Georgia Cancer Center while two additional clinical trial sites are currently being activated for inclusion in the study, The University of Texas Southwestern and New York Medical College. In January 2024, Bio-Path announced successful completion of the first dose cohort in the Phase 1 clinical trial.